Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents

International Journal of Cancer

Volumn 72, Issue 5, 1997, Pages 801-809

  Filippini, Cristian ^a   Bisiach, Matteo ^a   Tagliabue, Giovanna ^a   D'Incalci, Maurizio ^a   Ubezio, Paolo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BROXURIDINE; CARZELESIN; MELPHALAN; TALLIMUSTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; GRANULOCYTOSIS; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZOFURANS; BODY WEIGHT; BONE MARROW CELLS; CELL CYCLE; CELL DIVISION; DISTAMYCINS; FLOW CYTOMETRY; INDOLES; LEUKOCYTE COUNT; MALE; MELPHALAN; MICE; MICE, INBRED STRAINS; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0030763108     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970904)72:5<801::AID-IJC16>3.0.CO;2-B     Document Type: Article

References (19)

1. BAISCH, H., GOHDE, W. and LINDEN, W.A., Analysis of PCP-data to determine the fraction of cells in the various phases of the cell cycle. Rad. Environ. Biophys., 12, 31-39 (1975).
2. BEGG, A.C., MCNALLY, N.J., SHRIEVE, D.C. and KARCHER, H., A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry, 6, 620-626 (1985).
3. BROGGINI, M., ERBA, E., PONTI, M., BALLINARI, D., GERONI, C., SPREAFICO, F. and D'INCALCI, M., Selective DNA interaction of the novel distamycin derivative fee 24517. Cancer Res., 51, 199-204 (1991).
4. D'INCALCI, M., DNA-minor-groove alkylators, a new class of anticancer agents. Ann. Oncol., 5, 877-878 (1994).
5. ERICKSON, L.C., LAURENT, G., SHARKEY, N.A. and KOHN, K.W., DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nuture (Lond.), 288, 727-729 (1980).
6. FRIED, W., KEDE, A. and BARONE, J., Effects of cyclophosphamide and of busulfan on spleen-colony-forming units and on hematopoietic stroma. Cancer Res., 37, 1205-1209 (1977)
7. GIANNI, A.M. and BONADONNA, G., High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery? Europ. J. Cancer clin. Oncol., 25, 1027-1030 (1989).
8. GIANNI, A.M., SIENA, S., BREGNI, M., TARELLA, C., STERN, A.C., PILERI, A. and BONADONNA, G., Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet, ii, 580-585 (1989).
9. HENRAR, R.E., RATKE, C.C. and EARHART, R.H., Toxicology profile of carzelesin (u-80244), a prodrug cyclopropylpyrroloindolo analog [Abstract]. Proc. Ann. Meet. Amer. Assoc. Cancer Res., 34, A2558 (1993).
10. HIGASHIKUBO, R., WHITE, R.A. and ROTI ROTI, J.L., Flow cytometric BrdUrd-pulse-chase study of heat-induced cell-cycle progression delays. Cell Proliferation. 26, 337-348 (1993).
11. HOUGHTON, P.J., CHESHIRE, P.J., HALLMAN, J.D.I.I. and HOUGHTON, J.A., Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 36, 45-52 (1995).
12. LI, L.H., DEKONING, T.F., KELLY, R.C., KRUEGER, W.C., MCGOVERN, J.P., PADBURY, G.E., PETZOLD, G.L., WALLACE, T.L., OUDING, R.J., PRAIRIE, M.D. and GEBHARD, I., Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52, 4904-4913 (1992).
13. NISSEN-MEYER, R. and HOST, H., A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard. Cancer Chemother. Rep., 9, 51-55 (1960).
14. PEZZONI, G., GRANDI, M., BIASOLI, G., CAPOLONGO, L., BALLINARI, D., GIULIANI, F.C., BARBIERI, B., PASTORI, A., PESENTI, E. and MONGELLI, N., Biological profile of fce 24517, a novel benzoyl mustard analogue of distamycin A. Brit. J. Cancer, 64, 1047-1050 (1991).
15. PUNT, C.J.A., AWADA, A., JANSSENS, A., KERGER, J., GROOT, Y., VAN TELLINGEN, O., WANDERS, J., VERWEIJ, J., WAGENER, M.J. and PICCART, M.J., Carzelesin (U-80,244): toxicity patterns and pharmacokinetic data of two phase I studies. Ann. Oncol., 7 (Suppl. 1), 30 (1996).
16. SESSA, C., PAGANI, L.O., ZURLO, M.G., DE JONG, J., HOFMANN, C., LASUS, M., MARRARI, P., BENEDETTI, M.S. and CAVALLI, F., Phase 1 study of the novel distamycin derivative tallimustine (FCE 24517). Ann. Oncol., 5, 901-907 (1994).
17. UBEZIO, P., FILIPPESCHI, S. and SPINELLI, L., Method for kinetic analysis of drug-induced cell cycle perturbations. Cytometry, 12, 119-126 (1991).
18. UBEZIO, P., TAGLIABUE, G., SCHECHTER, B. and AGUR, Z., Increasing 1-beta-d-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Res., 54, 6446-6451 (1994).
19. WOLFF, I., BENCH, K., BEIJNEN, J., BRUNTSCH, F., CAVALLI, F., DE JONG, J., GROOT, Y., VAN TELLINGEN, O., WANDERS, J. and SESSA, C. for the EARLY CLINICAL STUDIES GROUP OF THE EORTC, Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res., 2, 1717-1723 (1996).